Orbitofrontal and striatal metabolism, volume, thickness and structural connectivity in relation to social anhedonia in depression: A multimodal study

• Published in: NeuroImage clinical Vol. 41; p. 103553
• Main Authors: Donnelly, Brianna M., Hsu, David T., Gardus, John, Wang, Junying, Yang, Jie, Parsey, Ramin V., DeLorenzo, Christine
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Inc 01.01.2024; Elsevier
• Subjects: Brain imaging; Major depression disorder; Orbitofrontal cortex; Regular; Social anhedonia; SSRI treatment; FDG-PET; Orbitofrontal cortex; Brain imaging; BF; MRI; SSRI treatment; MRGlu; MADRS; MDD; OFC; Social anhedonia; SCID-IV; SSRI; Major depression disorder; MP-RAGE; RSAS; FA; DTI/DSI; HAM-D
• ISSN: 2213-1582; 2213-1582
• DOI: 10.1016/j.nicl.2023.103553

•Social anhedonia was inversely correlated with medial OFC-amygdala connectivity.•However, OFC-amygdala connectivity did not account for the majority of the variance.•No other relationship was found between social anhedonia and metabolism, volume, thickness, or structural connectivity.•Results indicate that OFC neurobiology does not fully elucidate social anhedonia. Social anhedonia is common within major depressive disorder (MDD) and associated with worse treatment outcomes. The orbitofrontal cortex (OFC) is implicated in both reward (medial OFC) and punishment (lateral OFC) in social decision making. Therefore, to understand the biology of social anhedonia in MDD, medial/lateral OFC metabolism, volume, and thickness, as well as structural connectivity to the striatum, amygdala, and ventral tegmental area/nucleus accumbens were examined. A positive relationship between social anhedonia and these neurobiological outcomes in the lateral OFC was hypothesized, whereas an inverse relationship was hypothesized for the medial OFC. The association between treatment-induced changes in OFC neurobiology and depression improvement were also examined. 85 medication-free participants diagnosed with MDD were assessed with Wisconsin Schizotypy Scales to assess social anhedonia and received pretreatment simultaneous fluorodeoxyglucose positron emission tomography (FDG-PET) and magnetic resonance imaging (MRI), including structural and diffusion. Participants were then treated in an 8-week randomized placebo-controlled double-blind course of escitalopram. PET/MRI were repeated following treatment. Metabolic rate of glucose uptake was quantified from dynamic FDG-PET frames using Patlak graphical analysis. Structure (volume and cortical thickness) was quantified from structural MRI using Freesurfer. To assess structural connectivity, probabilistic tractography was performed on diffusion MRI and average FA was calculated within the derived tracts. Linear mixed models with Bonferroni correction were used to examine the relationships between variables. A significantly negative linear relationship between pretreatment social anhedonia score and structural connectivity between the medial OFC and the amygdala (estimated coefficient: −0.006, 95 % CI: −0.0108 – −0.0012, p-value = 0.0154) was observed. However, this finding would not survive multiple comparisons correction. No strong evidence existed to show a significant linear relationship between pretreatment social anhedonia score and metabolism, volume, thickness, or structural connectivity to any of the regions examined. There was also no strong evidence to suggest significant linear relationships between improvement in depression and percent change in these variables. Based on these multimodal findings, the OFC likely does not underlie social anhedonia in isolation and therefore should not be the sole target of treatment for social anhedonia. This is consistent with previous reports that other areas of the brain such as the amygdala and the striatum are highly involved in this behavior. Relatedly, amygdala-medial OFC structural connectivity could be a future target. The results of this study are crucial as, to our knowledge, they are the first to relate structure/function of the OFC with social anhedonia severity in MDD. Future work may need to involve a whole brain approach in order to develop therapeutics for social anhedonia.